{"disease":{"id":"hemophagocytic-lymphohistiocytosis","name":"hemophagocytic lymphohistiocytosis"},"drugs":{"marketed":[{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Megakaryocyte Erythroid Potent Protocadherin-related Protein (MEPEP) associated Hemophagocytic Lymphohistiocytosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"emapalumab-lzsg","indication_name":"Primary hemophagocytic lymphohistiocytosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Emapalumab-Lzsg","company_name":"Swedish Orphan Biovitrum","drug_phase":"discontinued","molecular_target":"Interferon gamma","drug_class":"Interferon gamma Blocker [EPC]","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Emapalumab-lzsg is a monoclonal antibody that binds to and neutralizes interferon gamma (IFNγ). Nonclinical data suggest that IFNγ plays a pivotal role in the pathogenesis of HLH by being hypersecreted."},{"drug_id":"emapalumab","indication_name":"Primary hemophagocytic lymphohistiocytosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gamifant","generic_name":"EMAPALUMAB","company_name":"Novimmune S.A.","drug_phase":"marketed","molecular_target":"Interferon gamma","drug_class":"Interferon gamma Blocker [EPC]","quality_score":55,"revenue":null,"mechanism":"Gamifant works by blocking the action of interferon gamma, a protein that helps coordinate the immune response."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03827343","title":"Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06339177","title":"Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04077905","title":"Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT05841342","title":"Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":128,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT03510650","title":"Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT03742115","title":"Etoposide in the First-line Treatment of Adult EBV-HLH","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT07488728","title":"Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Beijing Children's Hospital","has_results":false},{"nct_id":"NCT04120090","title":"Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT02069899","title":"A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":true},{"nct_id":"NCT05315336","title":"L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT03795909","title":"Ruxolitinib Combined With Dexamethasone for HLH","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Capital Research Institute of Pediatrics","has_results":false},{"nct_id":"NCT03259230","title":"Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":true},{"nct_id":"NCT03312751","title":"Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":true},{"nct_id":"NCT05001737","title":"Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":true},{"nct_id":"NCT06951971","title":"Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT05384743","title":"Rituximab Monotherapy for EBV-HLH and CAEBV","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT02472054","title":"Treatment of Familiar Lymphohistiocytosis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05775705","title":"L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT07525466","title":"Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT07531069","title":"Efficacy and Safety of Interferon-Gamma Monoclonal Antibody Combined With Dexamethasone in the Treatment of Refractory Adult Secondary Hemophagocytic Lymphohistiocytosis","phase":"","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05546060","title":"Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT05164978","title":"DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT05137522","title":"Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT06131489","title":"Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT07424222","title":"Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":16,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT06038422","title":"GTP Regimen in the Treatment of Refractory/Recurrent HLH","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT05744063","title":"A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":true},{"nct_id":"NCT06135922","title":"Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":9,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT06587191","title":"Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":7,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}